Incyte's Oncology Strategy: Putting Its Eggs In Many Mechanistic Baskets
Commercial success with Jakafi allows parallel development of many new cancer drug mechanisms beyond the IDO1 inhibitor epacadostat, which is on a fast track.
Commercial success with Jakafi allows parallel development of many new cancer drug mechanisms beyond the IDO1 inhibitor epacadostat, which is on a fast track.